Bioenvision to Hold Fiscal 2005 Year-End Financial Results Conference Call Tuesday, September 27, 2005
September 22 2005 - 7:00AM
Business Wire
Bioenvision (NASDAQ NM: BIVN) will release fiscal 2005 year-end
financial results before the market opens on Tuesday, September 27,
2005. Christopher B. Wood, M.D., chairman and CEO of Bioenvision,
and David P. Luci, CFO and general counsel, will host an investment
conference call beginning at 8:00 a.m. Eastern Daylight Time on
Tuesday, September 27, 2005 to discuss these results and to answer
questions. To participate in the live call by telephone, please
dial 877-825-5811 from the U.S. and Canada or 973-582-2767 from
outside the U.S and Canada. A telephone replay of the call will be
available beginning at 10 a.m. EDT September 27, 2005 through
midnight on October 4th, 2005 by dialing 877-519-4471 (U.S. or
Canada) or 973-341-3080 (outside the U.S./ Canada) and entering
reservation number 6517269. Those interested in listening to the
conference call live via the Internet may do so by visiting
Bioenvision's web site at www.bioenvision.com. To listen to the
live call, please go to the web site 15 minutes prior to its start
to register, download, and install the necessary audio software. A
replay of the call will be available on the web site for 14 days.
About Bioenvision Bioenvision's primary focus is the acquisition,
development and distribution of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products
for the treatment of cancer, including: Clofarabine (in
co-development with Genzyme Corporation), Modrenal(R) (for which
Bioenvision has obtained regulatory approval for marketing in the
United Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products
in clinical trials. Bioenvision is also developing anti-infective
technologies, including the OLIGON technology; an advanced
biomaterial that has been incorporated into various FDA approved
medical devices. For more information on Bioenvision please visit
our web site at www.bioenvision.com. Certain statements contained
herein are "forward-looking" statements (as such term is defined in
the Private Securities Litigation Reform Act of 1995). Because
these statements include risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to:
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's
compounds under development in particular; the potential failure of
Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure
to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioenvision's
business, structure or projections; the development of competing
products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in
Bioenvision's filings with the SEC. Bioenvision disclaims any
obligation to update these forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024